NCT04845139 is a NA clinical trial of Nivolumab in Refractory Central Nervous System Lymphoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04845139?

NCT04845139 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04845139?

Interventions in NCT04845139: Nivolumab.

What condition does NCT04845139 study?

NCT04845139 studies Refractory Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Primary Central Nervous System Lymphoma.

Is NCT04845139 still recruiting?

NCT04845139 is currently status unknown. Last updated 7 July 2022.

Last reviewed 2022-07-07 · How we verify

NCT04845139

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Status unknown NA Last updated 7 July 2022

What this trial tests

NA trial testing Nivolumab in Refractory Central Nervous System Lymphoma in 1 participant. Status unknown.

Timeline

2 July 2022

Primary endpoint
30 October 2022

30 November 2022

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	2 July 2022
Primary completion	30 October 2022
Estimated completion	30 November 2022
Sites	1 location across China

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →

Conditions studied

Refractory Central Nervous System Lymphoma — all drugs for Refractory Central Nervous System Lymphoma →
Relapsed Primary Central Nervous System Lymphoma — all drugs for Relapsed Primary Central Nervous System Lymphoma →
Primary Central Nervous System Lymphoma — all drugs for Primary Central Nervous System Lymphoma →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with Refractory Central Nervous System Lymphoma or Relapsed Primary Central Nervous System Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation.
Cao J, Xiong S, Zhang S, Yue N, et al · · 2025 · PMID 41080552 · DOI 10.3389/fimmu.2025.1647045

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Refractory Central Nervous System Lymphoma

Currently open trials in the same condition.

NCT04906902 — Acalabrutinib in CNSL · Phase 1, PHASE2 · active not recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04845139 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 7 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04845139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing